CYBG.LSE VanEck Bionic Engineering UCITS ETF A Acc GBP

ETF Healthcare Equity VanEck Asset Management B.V. London Exchange
- GBP
No recent price
Total assets
4.75M
Expense ratio
0.57%
Dividend yield
-
1-year return
-2.63%
Holdings
24
Since
2022

Fund data as reported by the issuer, updated Nov 3, 2026. Total assets are in the fund's base currency.

What does CYBG.LSE invest in?

Tracks Morningstar Gbl Health NR USD
  • Mostly US stocks (76.9%)
  • Largest sector: Healthcare (100.0%)
  • Largest region: North America (81.2%)
  • Top 3 holdings: 32.3% of the fund

Asset allocation

  • US stocks 76.9%
  • Non-US stocks 19.5%
  • Cash 0.1%

Top holdings

All holdings, sectors and regions

VanEck Bionic Engineering UCITS ETF A Acc GBP performance

Sharpe ratio 0.15
This year
-4.59%
1 year
-2.63%
3 years
+5.79%
5 years
0.00%

Volatility 18.7% over 1 year and 19.0% over 3 years. Moderate, similar to a broad stock index.

Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers

CYBG.LSE price

Prices on the chart can differ slightly from the closing prices StockSummer shows.

About VanEck Bionic Engineering UCITS ETF A Acc GBP

CYBG PLC, through its subsidiaries, provides retail and business banking products and services to individuals and businesses under the Clydesdale Bank, Yorkshire Bank, B, and Virgin Money brands in the United Kingdom. It operates through SME Banking and Retail Banking segments. The SME Banking segment offers a range of banking products and services, including business current accounts; and secured and unsecured term loans, business overdrafts, and invoice and asset financing…

Full fund profile